Succeed with Sirion – Vaccine Strategy

Lasse Neukirch  and colleagues, including Christian Thirion, Dr., CEO and Founder of SIRION Biotech, developed a vaccine strategy that could represent a novel tool to successfully target diverse ERV-bearing tumors in patients with cancer. The vaccine strategy led them to find that T cell responses were strong enough to prevent colorectal CT26 tumor growth and progression in BALB/c mice after a single vaccination before or after tumor challenge. Read the full paper here: https://bit.ly/Sir90.